The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
The metabolism and anti-atherogenic properties of HDL
Open accessAbstract
Population studies have shown that plasma HDL levels correlate inversely with cardiovascular disease risk. In recent years there has been intense interest in developing strategies for exploiting these cardioprotective properties by increasing HDL levels. While this approach has considerable merit, it is important to recognize that HDL are structurally and functionally diverse and consist of numerous, highly dynamic subpopulations of particles that do not all inhibit atherosclerosis to the same extent. For this reason it is essential to assess HDL subpopulation distribution and functionality when considering therapeutic interventions that raise HDL levels. This review documents what is known about the relationship between the metabolism and function of HDL subpopulations and how this affects their cardioprotective properties.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lowered levels of lipoprotein sub-fractions HDL2 and HDL3 are considered to increase CVD risk, although HDL3 may be less protective in the presence of MetS [15].”
Citations
Cites
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationIdentification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor
Acton, S., Rigotti, A., Landschulz, K. T., Xu, S., Hobbs, H. H., & Krieger, M. (1996) · Science · doi:10.1126/science.271.5248.518 · Cited by 2,026
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
Self-citationNew Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport
Lewis, G. F., & Rader, D. J. (2005) · Circulation Research · doi:10.1161/01.res.0000170946.56981.5c · Cited by 1,104
Effect of Torcetrapib on the Progression of Coronary Atherosclerosis
Nissen, S. E., Tardif, J., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., Rużyłło, W., Bachinsky, W., Lasala, G. P., & Tuzcu, E. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070635 · Cited by 968
High-Density Lipoproteins Inhibit Cytokine-Induced Expression of Endothelial Cell Adhesion Molecules
COCKERILL, G. W., Rye, K., Gamble, J. R., Vadas, M. A., & Barter, P. J. (1995) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.15.11.1987 · Cited by 788
Self-citationEffects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
Badimón, J. J., Badimón, L., & Fuster, V. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114558 · Cited by 764
Endothelial and Antithrombotic Actions of HDL
Mineo, C., Deguchi, H., Griffin, J. H., & Shaul, P. W. (2006) · Circulation Research · doi:10.1161/01.res.0000225982.01988.93 · Cited by 663
Cited by
Sorted by citations
Progress and challenges in translating the biology of atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2011) · Nature · doi:10.1038/nature10146 · Cited by 4,010
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
MicroRNAs in metabolism and metabolic disorders
Rottiers, V., & Näär, A. M. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3313 · Cited by 1,156
HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms
Navab, M., Reddy, S. T., Lenten, B. J. V., & Fogelman, A. M. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.222 · Cited by 666
Schalkwijk, C., & Stehouwer, C. D. A. (2019) · Physiological Reviews · doi:10.1152/physrev.00001.2019 · Cited by 649
Metadata
- Authors
- Rye, K.-A., Bursill, C. A., Lambert, G., Tabet, F., & Barter, P. J.
- Affiliations
- The University of Sydney (AU)
- The Heart Research Institute (AU)
- Corresponding author
- Rye, Kerry-Anne
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2009-04
- Volume
- 50
- Pages
- S195-S200
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC2674714
- OpenAlex
- W1967702791
- Cited by
- 331
- References
- 51
- Citations by year
- 2026: 13 · 2025: 14 · 2024: 12 · 2023: 17 · 2022: 15 · 2021: 16 · 2020: 16 · 2019: 17 · 2018: 21 · 2017: 13 · 2016: 9 · 2015: 27 · 2014: 21 · 2013: 48 · 2012: 20
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- HDL metabolism, HDL subpopulations, atherosclerosis, cardioprotection, cardiovascular risk, HDL function, HDL-targeted therapy
- MeSH terms
- Animals, Antioxidants, Humans, Inflammation, Cholesterol, HDL, Genetic Heterogeneity, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
